

CLAIMS

1. Use of gevokizumab or a functional fragment thereof in the manufacture of a medicament for the treatment and/or prevention of a cancer having at least partial inflammatory basis in a patient in need thereof, wherein said patient has high sensitivity C-reactive protein (hsCRP) equal to or greater than about 2mg/L before first administration of gevokizumab or functional fragment thereof.

2. The use according to claim 1, wherein the high sensitivity C-reactive protein (hsCRP) level of said patient has reduced by at least 20% compared to baseline assessed at least about 3 months after first administration of gevokizumab or functional fragment thereof.

3. Use of gevokizumab or a functional fragment thereof in the manufacture of a medicament for the treatment and/or prevention of a cancer having at least partial inflammatory basis in a patient in need thereof, wherein the high sensitivity C-reactive protein (hsCRP) level or the interleukin-6 (IL-6) level of said patient has reduced by at least 20% compared to baseline assessed at least about 3 months after first administration of gevokizumab or functional fragment thereof.

4. Use of gevokizumab or a functional fragment thereof in the manufacture of a medicament for the treatment of a cancer having at least partial inflammatory basis, wherein gevokizumab or a functional fragment thereof is administered at a dose of about 30 mg to about 240 mg per treatment.

5. The use according to any one of the preceding claims, wherein gevokizumab or a functional fragment thereof is administered at a dose of about 30 mg to about 180 mg per treatment.

6. The use according to any one of the preceding claims, wherein gevokizumab or a functional fragment thereof is administered at a dose of about 30 mg, about 60 mg, about 90 mg, or about 120 mg per treatment.

7. The use according to any one of the preceding claims, wherein said cancer having at least partial inflammatory basis is selected from the list consisting of lung cancer, especially non-small cell lung cancer (NSCLC), colorectal cancer (CRC), melanoma, gastric cancer (including esophageal cancer), renal cell carcinoma (RCC), breast cancer, prostate cancer, head and neck cancer, bladder cancer, hepatocellular carcinoma (HCC), ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer,

neuroendocrine cancer, multiple myeloma, acute myeloblastic leukemia (AML), and biliary tract cancer.

8. The use according to any one of the preceding claims, wherein said cancer having at least partial inflammatory basis is selected from the list consisting of colorectal cancer (CRC), renal cell carcinoma (RCC), and gastric cancer.

9. The use according to any one of the preceding claims, wherein said patient has high sensitivity C-reactive protein (hsCRP) equal to or greater than about 2 mg/L, equal to or greater than 4 mg/L, or equal to or greater than 10 mg/L before first administration of gevokizumab or functional fragment thereof.

10. The use according to any one of the preceding claims, wherein the high sensitivity C-reactive protein (hsCRP) level of said patient has reduced to below about 5 mg/L, 3.5 mg/L, or 2.3 mg/L assessed at least about 3 months after first administration of gevokizumab or functional fragment thereof.

11. The use according to any one of the preceding claims, wherein gevokizumab or a functional fragment thereof is administered every four weeks (monthly).

12. Use of gevokizumab or a functional fragment thereof in the manufacture of a medicament for the treatment of a cancer having at least partial inflammatory basis in a patient in need thereof, wherein said use comprises administering a dose of 30 mg to 120 mg of gevokizumab or a functional fragment thereof intravenously every four weeks (monthly).

13. The use according to any one of the preceding claims, wherein gevokizumab or a functional fragment thereof is administered in combination with one or more therapeutic agent, e.g. chemotherapeutic agent.

14. The use according to any one of the preceding claims, wherein said one or more therapeutic agent, e.g. chemotherapeutic agent, is a general cytotoxic agent.

15. The use according to any one of the claims 1-13, wherein said one or more therapeutic agent, e.g. chemotherapeutic agent, is a VEGF inhibitor.

16. The use according to any one of claims 1-13, wherein said one or more therapeutic agent, e.g. chemotherapeutic agent, is a checkpoint inhibitor.

17. The use according to any one of claims 1-13, wherein said one or more therapeutic agent, e.g. chemotherapeutic agent, is a PD-1 inhibitor or PD-L1 inhibitor.

18. The use according to any one of the preceding claims, wherein gevokizumab or a functional fragment thereof is used in the prevention of recurrence or relapse of

colorectal cancer, renal cell carcinoma (RCC), or gastric cancer (including esophageal cancer) in a patient after said cancer has been surgically removed.